NCT06671509View on ClinicalTrials.gov

Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 22, 2024

Primary Completion Date

April 18, 2024

Study Completion Date

August 7, 2024

Conditions

InsomniaHepatic Impairment

Interventions

DRUG

YZJ-1139

Single oral dose, 20 mg tablet

Trial Locations (1)

Unknown

The First Hospital of Jilin University, Changchun

All Listed Sponsors

lead

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT06671509 - Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment | Biotech Hunter | Biotech Hunter